Randomized clinical trial showed significant improvement in overall survival with glasdegib.
Researchers investigated the safety and efficacy of combination therapy with azacytidine and nivolumab for relapsed/refractory AML.
A snapshot of an international Commission's report on the issues inherent with adverse event reports of hematologic malingnancies in clinical trials.
A prospective cohort study from Denmark investigated the link between maternal hormonal contraception use before — more than 3 months and within 3 months — and during pregnancy and risk of leukemia in their children.
Increased risk of on-therapy relapse, relapse after completing therapy versus children with ALL
Lumoxiti, a CD22-directed cytotoxin, has been approved for adult patients who have had at least two prior therapies for the disease.
In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.
Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.
A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.
Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.
High-dose melphalan is a frequently before ASCT in MM, but is associated with high rates of adverse events.
Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.
A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.
A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.
Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.
A retrospective chart review was conducted to determine if adding lorazepam to granisetron would improve CINV prevention in pediatric patients with newly diagnosed ALL.
Analysis of a cohort of patients with newly diagnosed multiple myeloma focused on the effect of post-ASCT maintenance therapy on health-related QOL and clinical outcomes.
In this study, researchers investigated the effects of exercise on physical and psychological recovery after autoHSCT for multiple myeloma.
De-escalation of TKI therapy may be an effective management strategy among patients with CML who have responded to therapy.
A retrospective study sought to evaluate outcomes for patients with CLL who were treated with FCR, a highly effective treatment, and initially had refractory disease, experienced relapse early, or were unable to complete therapy due to toxicity.
In this study, researchers assigned 75 patients with newly diagnosed Philadelphia chromosome (Ph)-positive CML-CP to receive dasatinib 50 mg once daily.
Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway
[Cancer Management and Research] In this study, researchers explored the potential of andrographolide and topotecan, separately and together, in the in vitro treatment of the U937 acute myeloid leukemic cell line.
In a prospective, longitudinal study, researchers investigated the potential for quality of life, fatigue, and physical functioning to return to previous levels in patients with AML after treatment.
[OncoTargets and Therapy] In a review of cancer stem cells (CSCs)/ovarian cancer stem cells (OCSCs), researchers discuss the implications of immunotherapy development based on studying cancer evolution by CSCs, and targeting OCSC surface markers to develop CAR-T immunotherapy.
An assessment of more than 71,000 patients with leukemia demonstrated the difference in outcomes for patients admitted to hospital on the weekend vs weekday. Findings were presented at the 2018 ASCO Annual Meeting.
Children's Oncology Group study reported on the effect of dexrazoxane on cardiotoxicity of anthracycline-containing regimens in pediatric patients with AML at the 2018 ASCO Annual Meeting.
Teaming up with multiple specialists to create an algorithm for managing AML in older patients improved clinician knowledge as well as provided patient-centered care, a presentation at 2018 ONS Annual Congress has shown.
Accelerated approval was granted by the FDA based on the results of a single-arm trial.
A presentation at 2018 ONS Congress described the success of a class focused on preparing patients and their families to management their care after discharge.
Slight changes in taste perceptions are noted in patients undergoing HSCT for hematologic cancers. In this study, researchers sought to determine how these changes affect quality of life and nutritional intake.
Researchers compared survival outcomes of thiotepa-based intensified RIC vs standard RIC among patients undergoing cord-blood transplantation (CBT).
Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?
[Cancer Management and Research] This report presents an assessment of the relationship of Bax/Bcl-2 expression and the clinical response of patients with AML treated with cytarabine plus daunorubicin, and their potential as biomarkers to predict chemotherapeutic outcomes.
Although many TKIs have well-documented cardiotoxic effects, results of a single-center prospective study that assessed effects of 1 year of therapy with imatinib or nilotinib in patients with CML demonstrated safety and efficacy of the 2 agents in this population.
This study examined the risk of secondary cancers among patients with CML who were treated with TKIs.
The US FDA approved expanding the indications for the agent to include pediatric and adult patients with B-cell precursor ALL who have minimal residual disease during or after treatment.
Inotuzumab ozogamicin (InO) use may have quality of life benefits for patients with R/R B-cell ALL, as well as producing improved clinical outcomes.
Based on results of 2 prospective studies, the FDA approved the use of nilotinib in pediatric patients older than 1 year with newly diagnosed Ph+ CML-CP and those with TKI-intolerant or resistant disease.
Some patients with chronic myeloid leukemia in chronic phase maintained TFR after receiving nilotinib, according to data from the ENESTfreedom study.
Researchers used mouse cells to determine activation levels of FcγRIIIa and FcγRI using obinutuzumab, rituximab and ofatumumab.
Results of the ENESTop study demonstrate the potential for patients with CML who had deep molecular response to achieve long-term treatment-free remission (TFR) after second-line nilotinib, increasing the focus of TFR as a therapeutic outcome.
Researchers present findings of a study assessing the value of SESM evaluations in patients with hematologic cancer prior to undergoing SCT at the NACNS 2018 Annual Conference.
What are key monitoring guidelines for patients with CLL being treated with venetoclax?
1. Phase 2, open-label study results suggest that treatment-free remission (TFR) of chronic myeloid leukemia (CML) for ≥48 weeks can be reached by over half of patients who have reached deep molecular response (DMR) after ceasing second-line nilotinib treatment. 2. The authors suggest that for patients who do not reach sustained DMR with imatinib, changing 
A previous single-site trial showed that patients with R/R B-cell ALL treated with tisagenlecleucel achieved high complete remission rates. In this study, investigators report on results after the scope of the study was expanded.
As supportive care improves, elderly patients may benefit from high-dose chemotherapy with autologous stem cell transplantation.
Investigators sought to determine the efficacy of 2-year rituximab maintenance therapy in elderly patients with CLL who achieve a complete response to abbreviated FCR induction therapy.
Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.
The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.
Recent study findings investigated the economic burden of patients with relapsed Ph-negative ALL, and the adverse events of special interest that are most likely to have the greatest impact. These findings were presented at ASH 2017.
A retrospective analysis of patients with CML determined prevalence of arterial thrombotic events in those receiving nilotinib as first-line treatment and prevalence by patient age. Data were presented at ASH 2017.
Despite advancements in treatment of CML, many patients still experience adverse effects of their disease and treatments. Therefore, researchers conducted a survey of patients to determine whether they felt assistance and support met their needs.
What is the concern behind PARP inhibitors and leukemia?
Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.
US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.
Comparison study via questionnaires assessed patients' and oncologists' views on likelihood of dying as a result of treatment shortly after beginning intensive or nonintensive chemotherapy for AML, and their views on prognosis 1 month later.
Despite its high response rate, researchers are finding that patients with endothelial activation prior to lymphodepletion chemotherapy are at greater risk of neurologic adverse events after undergoing CAR T-cell therapy for relapsed/refractory B-ALL, CLL, or NHL.
[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.
Results of this double-blind, phase 3 study reports on impact of lenalidomide maintenance therapy on risk of disease progression in patients with CLL who did not achieve minimal residual disease state after first-line chemoimmunotherapy.
Gemtuzumab ozogamicin (Mylotarg) was granted US FDA approval for the treatment of relapsed or refractory CD-33 positive AML in patients ages 2 years and older and newly diagnosed CD-33 positive AML in adult patients.
Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.
The first FDA approval of a CAR T cell therapy is granted for the treatment of B-cell precursor ALL. FDA also approves rheumatoid arthritis medication for the management of cytokine release syndrome, a common and serious adverse effect of CAR T cell therapy
Time to disease progression was significantly prolonged in patients with multiple myeloma who received lenalidomide therapy after ASCT.
For adults with relapsed or refractory AML who have an IDH2 genetic mutation
Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.
Comparison study demonstrates early response and survival benefits of VTD, VTDC, and TAD regimens in transplant-eligible patients with newly diagnosed multiple myeloma.
Hospice services and effective health care strategies are underutilized by patients with AML leading to suboptimal end-of-life care.
In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.
Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.
Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin
Study reports that patients with classic relapsed/refractory Hodgkin lymphoma who received nivolumab after ASCT experienced high rates of response regardless of previous history with brentuximab vedotin.
Children with extramedullary relapse of CD19+ acute lymphoblastic leukemia experienced a potent and durable response to the immunotherapy.
Palliative care added to transplant care improved relief from depression and PTSD symptoms following hematopoietic stem cell transplantation.
A nurse-led team developed a tracking tool that created a vaccination schedule from transplant date forward for autologous hematopoietic stem cell transplant recipients.
An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.
Patients with myeloma that underwent transplantation in addition to RVD had significantly longer median progression-free survival compared to the group that received RVD alone.
Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.
The efficacy of imatinib for CML treatment persisted over time and long-term administration was not associated with unacceptable cumulative effects.
Results from the TOWER trial demonstrate that blinatumomab (Blincyto) effectively improved OS in high-risk B-cell precursor ALL.
A novel agent, letermovir, reduced incidence of CMV in patients undergoing stem cell transplantation for hematologic malignancies.
The site of cancer care may partially explain survival differences between children and AYAs with ALL.
Genome editing technology illustrates progression of normal blood cells to leukemia.
Pediatric patients and their parents tend to overestimate adherence to anticancer medicine regimen.
Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.
Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.
Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.
Researchers determined the curative potential of allogenic hematopoetic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia in second complete remission.
Ibrutinib, idelalisib, ponatinib, and ruxolitinib are each associated with a variety of potential adverse effects and oncology nurses must be aware of these to successfully monitor for them.
Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.
Azathioprine for the treatment of autoimmune disorders is significantly associated with an increased risk of acute myeloid leukemia and myelodysplastic syndromes.
Three specific genetic alterations may help identify pediatric patients with AMKL at high risk who may benefit from allogeneic stem cell transplants.
This fact sheet reviews bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) as they relate to the cancer treatment.
I was surprised to see an order for arsenic recently. What is this being used for?
An assessment of depression in patients before autologous or allogeneic HCT demonstrated that the condition impacts overall survival and risk of GVDH in patients with hematologic malignancies.
Results of this study reveal the impact on quality of life and consequent adherence to therapy for patients with CML-CP receiving nilotinib as second-line therapy.
Researchers evaluated the molecular response in patients with CML-CP treated with pioglitazone in combination with imatinib, the results of which suggest that adding pioglitazone to a kinase inhibitor may have a synergistic effect.
In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.
Study results indicate that herpetic cytomegalovirus infection prior to birth subjects the child to increased odds of developing pediatric acute lymphoblastic leukemia.
A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.
What precautions should be taken to prevent tumor lysis syndrome (TLS) in patients receiving venetoclax (Venclexta)?
Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.
Abnormal lipid metabolism is observed in patients with CLL, prompting an investigation to determine if prevalence of metabolic syndrome is higher in patients with CLL and whether lipid-lowering medications impact survival.
Sign Up for Free e-newsletters
- Cancer Treatment and Research: What Lies Ahead in 2019
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma
- Regular Physical Activity — Even Initiated Postdiagnosis — Improves Survival for Cancer Patients
- Gastrointestinal Perforation Complicates Management of Mantle Cell Lymphoma
- Brain Exercise Program Eases Chemobrain in Breast Cancer Survivors
- Hormone Therapy for Breast Cancer (Fact Sheet)
- Counseling on the Dangers of Vaping
- Radical Prostatectomy vs Active Surveillance: Results of Nearly 3 Decades of Follow-up
- Potential of Fecal Microbiota Transplantation in Managing Immunotherapy-Associated Colitis
- Ixazomib Maintenance After ASCT Improves Progression-Free, Overall Survival in Multiple Myeloma
- Evolutionary Role of Chemotherapy in Advanced Nasopharyngeal Carcinoma: A Literature-based Network Meta-analysis
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Gastrointestinal Perforation Complicates Management of Mantle Cell Lymphoma
- Modernizing Eligibility Criteria Could Increase Access to, Participation in Clinical Trials
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|